TORONTO (Reuters) –
Neurochem Inc. reported positive data on Wednesday for its drug to treat Alzheimer's and said it expects Alzhemed to start phase III trials in June. Montreal-based Neurochem said that out of 11 patients with mild Alzheimer's, 82 percent showed stabilized or improved cognitive function. It expects to release data on seven patients with moderate Alzheimer's at a July conference.
"Unlike current therapies, which treat just the symptoms of the disease, Alzhemed seems to address the underlying cause," said Dr. Serge Gauthier, professor of neurology and neurosurgery at McGill University in Montreal. "If cleared by regulatory agencies, Alzhemed could provide an important treatment to benefit millions of Alzheimer patients," Gauthier said at a symposium on advances in Alzheimer therapy where Neurochem presented the data.
Neurochem said it plans to start phase III clinical trials for Alzhemed in North America in June. Pivotal trials in Europe could start late this year or early in 2005. Alzhemed, an orally administered drug, reduces a plaque formation in the brain caused by a protein. Most Alzheimer's researchers believe that the cause of the disease is the formation of plaque in the brain, though that has yet to be definitely proved.
Source: Yahoo! Health News